Opgen Inc Cmn Stk (OPGN) 1.67 $OPGN OpGen, Inc.
Post# of 273242
Posted On: 09/22/2016 9:02:37 AM
Opgen Inc Cmn Stk (OPGN) 1.67 $OPGN
OpGen, Inc. to Host Anti-Infectives Roundtable at the World Anti-Microbial Resistance Congress
GlobeNewswire - Thu Sep 08, 6:30AM CDT
OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in Washington, D.C. OpGen CEO Evan Jones will lead a presentation titled "Harnessing the power of informatics and genomic analysis to provide complete MDRO solutions" on Thursday, September 8 at 3:05 p.m. ET.
OPGN: 1.67 (unch)
OpGen to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
GlobeNewswire - Wed Sep 07, 6:30AM CDT
OpGen, Inc. (NASDAQ:OPGN) an informatics and genomic analysis company, announces that Evan Jones, the Company's Chairman and Chief Executive Officer, will provide a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference. Mr. Jones' presentation will be on Monday, September 12, 2016 at 3:25 p.m. Eastern time. The conference is being held from September 11 to 13 in New York City.
OPGN: 1.67 (unch)
OpGen Reports 2016 Second Quarter Financial Results and Provides Business Update
GlobeNewswire - Tue Aug 09, 3:02PM CDT
OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the three and six months ended June 30, 2016. Highlights of the second quarter and recent weeks include:
OPGN: 1.67 (unch)
OpGen Announces Completion of the Intermountain Healthcare Retrospective MDRO Health Outcome Study
GlobeNewswire - Mon Aug 08, 10:25AM CDT
OpGen, Inc. (NASDAQ:OPGN), an informatics and genomic analysis company, announces the completion of its multi-drug resistant organisms (MDRO) health outcomes study with Intermountain Healthcare. It was a collaboration between Intermountain Healthcare and Enterprise Analysis Corporation (EAC) in a retrospective study to explore multi-drug resistant organisms and Clostridium difficile trends throughout the Intermountain Healthcare System over an 8-year period (2008-2015). The study was requested and funded by OpGen.
OPGN: 1.67 (unch)
OpGen, Inc. Announces Timing for Second Quarter Financial Results and Conference Call
GlobeNewswire - Tue Aug 02, 7:30AM CDT
OpGen, Inc. (NASDAQ:OPGN) today announced that financial results for the company's second quarter ended June 30, 2016 will be released Tuesday, August 9, 2016. The management team will host a conference call discussing the company's financial results and recent developments that day at 4:30 p.m. E.T.
OPGN: 1.67 (unch)
OpGen to Present at the 6th Annual LD Micro Invitational Conference
ACCESSWIRE - Thu Jun 02, 7:01AM CDT
GAITHERSBURG, MD / ACCESSWIRE / June 2, 2016 / OpGen, Inc. (NASDAQ: OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announced today that Kevin Krenitsky, president, will present at the 6th Annual LD Micro Invitational conference on June 7, 2016 at 2:30 p.m. Pacific Time. The conference is being held from June 7- 9 at the Luxe Sunset Boulevard Hotel in Los Angeles.
OPGN: 1.67 (unch)
OpGen Announces Closing of $10 Million Private Placement
GlobeNewswire - Fri May 20, 9:14AM CDT
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the first closing of a private placement financing raising gross proceeds of $10.4 million. The Company will use the net proceeds, after payment of offering expenses, to support the sales and marketing and continued research and development of the Company's rapid diagnostic and Acuitas Lighthouse(TM) bioinformatics products and services, and for general corporate purposes.
MRK: 62.70 (+0.76), OPGN: 1.67 (unch)
OpGen Supports New White House National Microbiome Initiative
GlobeNewswire - Tue May 17, 8:00AM CDT
OpGen, Inc. (NASDAQ:OPGN), a leading developer of precision medicine tools to combat infectious disease in global healthcare settings, supports the new White House National Microbiome Initiative (NMI) and its more than $121 million of strategic investments from various Federal agencies into interdisciplinary and multi-ecosystem microbiome research and tools development. The NMI was announced on May 13, 2016.
OPGN: 1.67 (unch)
OpGen Reports 2016 First Quarter Financial Results and Business Update
GlobeNewswire - Thu May 12, 3:01PM CDT
First quarter revenue increases 128% over prior year to $1.1 million
OPGN: 1.67 (unch)
OpGen Announces Pricing of $10 Million Private Placement
GlobeNewswire - Thu May 12, 8:00AM CDT
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the pricing of a private placement of units, each unit consisting of one share of common stock and one warrant to purchase 0.75 of one share of common stock, for an aggregate issuance of 9,053,556 shares of common stock and warrants to purchase 6,790,169 shares of common stock. Each unit will be sold at a price of $1.14375 per unit. The warrants will be exercisable beginning 90 days after the closing of the transaction, have an exercise price of $1.3125 per share of common stock and may be exercised for five years. The gross proceeds of the offering are $10.355 million. The Company will use the net proceeds, after payment of offering expenses to support the sales and marketing and continued research and development of the Company's rapid diagnostic and Acuitas Lighthouse bioinformatics products and services, and for general corporate purposes.
OPGN: 1.67 (unch)
OpGen, Inc. Announces Timing for First Quarter Financial Results and Conference Call
GlobeNewswire - Tue May 10, 1:03PM CDT
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today announced that financial results for the company's first quarter ended March 31, 2016 will be released Thursday, May 12, 2016. The management team will host a conference call discussing the company's financial results and recent developments that day at 4:30 p.m. E.T. The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (international) five minutes prior to the start of the call and providing passcode 2703412.
OPGN: 1.67 (unch)
OpGen and District of Columbia Hospital Association Complete First Citywide Quantification of Multidrug-Resistant Organism (MDRO) Prevalence in Washington, D.C.-based Healthcare Facilities
GlobeNewswire - Wed May 04, 6:30AM CDT
Consortium of Washington, D.C. Health Organizations and OpGen test over 1,000 patient samples for antibiotic resistant bacteria
OPGN: 1.67 (unch)
OpGen Appoints Harry J. D'Andrea to Board of Directors
GlobeNewswire - Mon May 02, 11:22AM CDT
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the appointment of Harry J. D'Andrea to the company's board of directors, effective April 29, 2016. He will serve as a member of the board's audit committee and will stand for reelection for a one-year term at the company's annual meeting of stockholders, to be held June 22, 2016.
OPGN: 1.67 (unch)
OpGen to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
GlobeNewswire - Wed Feb 03, 7:00AM CST
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces that Evan Jones, the Company's Chairman and Chief Executive Officer, will present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 11, 2016 at 2:45 p.m. Eastern time. The conference is being held from February 10 to 11 in New York City.
OPGN: 1.67 (unch)
OpGen, Inc., to Present at Noble Financial Capital Markets' 12th Annual Investor Conference
GlobeNewswire - Wed Jan 13, 3:00PM CST
OpGen, Inc. (NASDAQ:OPGN), a molecular diagnostics and bioinformatics company helping to guide antibiotic therapy and to assist healthcare providers in combatting multi-drug resistant infections, announced today that Chairman and Chief Executive Officer Evan Jones will present at the NobleCon12 - Noble Financial Capital Markets' 12th Annual Investor Conference on January 20, 2016, at 10:30 a.m. Eastern Standard Time. The conference is being held at Club Med in Sandpiper Bay, Florida from January 17-20.
OPGN: 1.67 (unch)
OpGen's QuickFISH Rapid Pathogen ID Test Demonstrates Clinical Utility and Cost Effectiveness in Community Hospital's Antimicrobial Stewardship Program
GlobeNewswire - Thu Dec 17, 7:30AM CST
OpGen, Inc. (NASDAQ:OPGN), a molecular diagnostics and bioinformatics company helping to guide antibiotic therapy and to assist healthcare providers in combatting multi-drug resistant infections, announced today that the American Journal of Clinical Pathology has published a study on the benefits of using the company's rapid Staphylococcus QuickFISH test at Winter Haven Hospital in Winter Haven, Fla.
OPGN: 1.67 (unch)
District of Columbia Hospital Association Chooses OpGen to Create Citywide Effort to Track Multidrug-Resistant Bacteria
GlobeNewswire - Wed Nov 18, 7:31AM CST
OpGen, Inc. (NASDAQ:OPGN) and the District of Columbia Hospital Association (DCHA) today announced that Washington DC's public health departments will oversee a comprehensive citywide evaluation, HARP-DC (Healthcare facility Antibiotic Resistance Prevalence-District of Columbia), to gauge the prevalence of the multidrug-resistant Gram-negative bacteria Carbapenem-resistant Enterobacteriaceae (CRE) in healthcare facilities throughout the District of Columbia. The DC Department of Health (DOH)-led study is being funded by the Centers for Disease Control and Prevention's (CDC's) Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Funding program for tracking healthcare-associated infections (HAI). The Department, in turn, has contracted OpGen to perform related laboratory services. The DC Department of Forensic Sciences-Public Health Laboratory (DFS-PHL) is also participating in the study by providing logistical support and by sequencing and banking isolates recovered from cultures.
OPGN: 1.67 (unch)
OpGen Reports Third Quarter Financial Results and Provides Business Update
GlobeNewswire - Thu Nov 12, 3:10PM CST
OpGen, Inc. (NASDAQ:OPGN), an early commercial-stage company using molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers combat multi-drug resistant infections, today reported financial results for the three and nine months ended September 30, 2015. Highlights of the third quarter of 2015 and recent weeks include:
OPGN: 1.67 (unch)
Data Show "Super Bug" Surveillance System Based on OpGen's Acuitas(R) Resistome Test Can Identify Potential Outbreaks in Hospitals and Improve Infection Control
GlobeNewswire - Mon Oct 12, 7:30AM CDT
OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that new data from a study with its Acuitas Resistome Test were presented on October 10 as an oral abstract at IDWeek 2015 by Michael Lin, M.D., M.P.H., an infectious disease physician and assistant professor of medicine at Rush University Medical Center in Chicago. The conference was held October 7 to 11 in San Diego. Dr. Lin and fellow researchers demonstrated how an Acuitas Resistome-based surveillance system can identify potential outbreaks to improve infection control, underscoring the need for healthcare facilities to implement use of molecular-based surveillance systems to detect potential outbreaks that may be caused by multidrug-resistant organisms (MDROs). The research was conducted under the support of the CDC Prevention Epicenters Program and affiliated with the REALM project, a multi-hospital voluntary surveillance network for monitoring multidrug-resistant organisms among Chicago hospital intensive care units and long-term acute care hospitals.
OPGN: 1.67 (unch)
OpGen to Present Data Showing Acuitas(R) Tests are Effective Tools for Investigating Transmission of "Super Bugs"
GlobeNewswire - Tue Sep 22, 7:15AM CDT
OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas Resistome Test and Acuitas Whole Genome Sequence (WGS) Analysis for multidrug-resistant organisms (MDROs) will be presented at the American Society for Microbiology's First Conference on Rapid Next-Generation Sequencing and Bioinformatic Pipelines for Enhanced Molecular Epidemiologic Investigation of Pathogens, to be held from September 24 to 27 in Washington, D.C.
OPGN: 1.67 (unch)
OpGen, Inc. to Host Anti-Infectives Roundtable at the World Anti-Microbial Resistance Congress
GlobeNewswire - Thu Sep 08, 6:30AM CDT
OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in Washington, D.C. OpGen CEO Evan Jones will lead a presentation titled "Harnessing the power of informatics and genomic analysis to provide complete MDRO solutions" on Thursday, September 8 at 3:05 p.m. ET.
OPGN: 1.67 (unch)
OpGen to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
GlobeNewswire - Wed Sep 07, 6:30AM CDT
OpGen, Inc. (NASDAQ:OPGN) an informatics and genomic analysis company, announces that Evan Jones, the Company's Chairman and Chief Executive Officer, will provide a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference. Mr. Jones' presentation will be on Monday, September 12, 2016 at 3:25 p.m. Eastern time. The conference is being held from September 11 to 13 in New York City.
OPGN: 1.67 (unch)
OpGen Reports 2016 Second Quarter Financial Results and Provides Business Update
GlobeNewswire - Tue Aug 09, 3:02PM CDT
OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the three and six months ended June 30, 2016. Highlights of the second quarter and recent weeks include:
OPGN: 1.67 (unch)
OpGen Announces Completion of the Intermountain Healthcare Retrospective MDRO Health Outcome Study
GlobeNewswire - Mon Aug 08, 10:25AM CDT
OpGen, Inc. (NASDAQ:OPGN), an informatics and genomic analysis company, announces the completion of its multi-drug resistant organisms (MDRO) health outcomes study with Intermountain Healthcare. It was a collaboration between Intermountain Healthcare and Enterprise Analysis Corporation (EAC) in a retrospective study to explore multi-drug resistant organisms and Clostridium difficile trends throughout the Intermountain Healthcare System over an 8-year period (2008-2015). The study was requested and funded by OpGen.
OPGN: 1.67 (unch)
OpGen, Inc. Announces Timing for Second Quarter Financial Results and Conference Call
GlobeNewswire - Tue Aug 02, 7:30AM CDT
OpGen, Inc. (NASDAQ:OPGN) today announced that financial results for the company's second quarter ended June 30, 2016 will be released Tuesday, August 9, 2016. The management team will host a conference call discussing the company's financial results and recent developments that day at 4:30 p.m. E.T.
OPGN: 1.67 (unch)
OpGen to Present at the 6th Annual LD Micro Invitational Conference
ACCESSWIRE - Thu Jun 02, 7:01AM CDT
GAITHERSBURG, MD / ACCESSWIRE / June 2, 2016 / OpGen, Inc. (NASDAQ: OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announced today that Kevin Krenitsky, president, will present at the 6th Annual LD Micro Invitational conference on June 7, 2016 at 2:30 p.m. Pacific Time. The conference is being held from June 7- 9 at the Luxe Sunset Boulevard Hotel in Los Angeles.
OPGN: 1.67 (unch)
OpGen Announces Closing of $10 Million Private Placement
GlobeNewswire - Fri May 20, 9:14AM CDT
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the first closing of a private placement financing raising gross proceeds of $10.4 million. The Company will use the net proceeds, after payment of offering expenses, to support the sales and marketing and continued research and development of the Company's rapid diagnostic and Acuitas Lighthouse(TM) bioinformatics products and services, and for general corporate purposes.
MRK: 62.70 (+0.76), OPGN: 1.67 (unch)
OpGen Supports New White House National Microbiome Initiative
GlobeNewswire - Tue May 17, 8:00AM CDT
OpGen, Inc. (NASDAQ:OPGN), a leading developer of precision medicine tools to combat infectious disease in global healthcare settings, supports the new White House National Microbiome Initiative (NMI) and its more than $121 million of strategic investments from various Federal agencies into interdisciplinary and multi-ecosystem microbiome research and tools development. The NMI was announced on May 13, 2016.
OPGN: 1.67 (unch)
OpGen Reports 2016 First Quarter Financial Results and Business Update
GlobeNewswire - Thu May 12, 3:01PM CDT
First quarter revenue increases 128% over prior year to $1.1 million
OPGN: 1.67 (unch)
OpGen Announces Pricing of $10 Million Private Placement
GlobeNewswire - Thu May 12, 8:00AM CDT
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the pricing of a private placement of units, each unit consisting of one share of common stock and one warrant to purchase 0.75 of one share of common stock, for an aggregate issuance of 9,053,556 shares of common stock and warrants to purchase 6,790,169 shares of common stock. Each unit will be sold at a price of $1.14375 per unit. The warrants will be exercisable beginning 90 days after the closing of the transaction, have an exercise price of $1.3125 per share of common stock and may be exercised for five years. The gross proceeds of the offering are $10.355 million. The Company will use the net proceeds, after payment of offering expenses to support the sales and marketing and continued research and development of the Company's rapid diagnostic and Acuitas Lighthouse bioinformatics products and services, and for general corporate purposes.
OPGN: 1.67 (unch)
OpGen, Inc. Announces Timing for First Quarter Financial Results and Conference Call
GlobeNewswire - Tue May 10, 1:03PM CDT
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today announced that financial results for the company's first quarter ended March 31, 2016 will be released Thursday, May 12, 2016. The management team will host a conference call discussing the company's financial results and recent developments that day at 4:30 p.m. E.T. The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (international) five minutes prior to the start of the call and providing passcode 2703412.
OPGN: 1.67 (unch)
OpGen and District of Columbia Hospital Association Complete First Citywide Quantification of Multidrug-Resistant Organism (MDRO) Prevalence in Washington, D.C.-based Healthcare Facilities
GlobeNewswire - Wed May 04, 6:30AM CDT
Consortium of Washington, D.C. Health Organizations and OpGen test over 1,000 patient samples for antibiotic resistant bacteria
OPGN: 1.67 (unch)
OpGen Appoints Harry J. D'Andrea to Board of Directors
GlobeNewswire - Mon May 02, 11:22AM CDT
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the appointment of Harry J. D'Andrea to the company's board of directors, effective April 29, 2016. He will serve as a member of the board's audit committee and will stand for reelection for a one-year term at the company's annual meeting of stockholders, to be held June 22, 2016.
OPGN: 1.67 (unch)
OpGen to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
GlobeNewswire - Wed Feb 03, 7:00AM CST
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces that Evan Jones, the Company's Chairman and Chief Executive Officer, will present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 11, 2016 at 2:45 p.m. Eastern time. The conference is being held from February 10 to 11 in New York City.
OPGN: 1.67 (unch)
OpGen, Inc., to Present at Noble Financial Capital Markets' 12th Annual Investor Conference
GlobeNewswire - Wed Jan 13, 3:00PM CST
OpGen, Inc. (NASDAQ:OPGN), a molecular diagnostics and bioinformatics company helping to guide antibiotic therapy and to assist healthcare providers in combatting multi-drug resistant infections, announced today that Chairman and Chief Executive Officer Evan Jones will present at the NobleCon12 - Noble Financial Capital Markets' 12th Annual Investor Conference on January 20, 2016, at 10:30 a.m. Eastern Standard Time. The conference is being held at Club Med in Sandpiper Bay, Florida from January 17-20.
OPGN: 1.67 (unch)
OpGen's QuickFISH Rapid Pathogen ID Test Demonstrates Clinical Utility and Cost Effectiveness in Community Hospital's Antimicrobial Stewardship Program
GlobeNewswire - Thu Dec 17, 7:30AM CST
OpGen, Inc. (NASDAQ:OPGN), a molecular diagnostics and bioinformatics company helping to guide antibiotic therapy and to assist healthcare providers in combatting multi-drug resistant infections, announced today that the American Journal of Clinical Pathology has published a study on the benefits of using the company's rapid Staphylococcus QuickFISH test at Winter Haven Hospital in Winter Haven, Fla.
OPGN: 1.67 (unch)
District of Columbia Hospital Association Chooses OpGen to Create Citywide Effort to Track Multidrug-Resistant Bacteria
GlobeNewswire - Wed Nov 18, 7:31AM CST
OpGen, Inc. (NASDAQ:OPGN) and the District of Columbia Hospital Association (DCHA) today announced that Washington DC's public health departments will oversee a comprehensive citywide evaluation, HARP-DC (Healthcare facility Antibiotic Resistance Prevalence-District of Columbia), to gauge the prevalence of the multidrug-resistant Gram-negative bacteria Carbapenem-resistant Enterobacteriaceae (CRE) in healthcare facilities throughout the District of Columbia. The DC Department of Health (DOH)-led study is being funded by the Centers for Disease Control and Prevention's (CDC's) Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Funding program for tracking healthcare-associated infections (HAI). The Department, in turn, has contracted OpGen to perform related laboratory services. The DC Department of Forensic Sciences-Public Health Laboratory (DFS-PHL) is also participating in the study by providing logistical support and by sequencing and banking isolates recovered from cultures.
OPGN: 1.67 (unch)
OpGen Reports Third Quarter Financial Results and Provides Business Update
GlobeNewswire - Thu Nov 12, 3:10PM CST
OpGen, Inc. (NASDAQ:OPGN), an early commercial-stage company using molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers combat multi-drug resistant infections, today reported financial results for the three and nine months ended September 30, 2015. Highlights of the third quarter of 2015 and recent weeks include:
OPGN: 1.67 (unch)
Data Show "Super Bug" Surveillance System Based on OpGen's Acuitas(R) Resistome Test Can Identify Potential Outbreaks in Hospitals and Improve Infection Control
GlobeNewswire - Mon Oct 12, 7:30AM CDT
OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that new data from a study with its Acuitas Resistome Test were presented on October 10 as an oral abstract at IDWeek 2015 by Michael Lin, M.D., M.P.H., an infectious disease physician and assistant professor of medicine at Rush University Medical Center in Chicago. The conference was held October 7 to 11 in San Diego. Dr. Lin and fellow researchers demonstrated how an Acuitas Resistome-based surveillance system can identify potential outbreaks to improve infection control, underscoring the need for healthcare facilities to implement use of molecular-based surveillance systems to detect potential outbreaks that may be caused by multidrug-resistant organisms (MDROs). The research was conducted under the support of the CDC Prevention Epicenters Program and affiliated with the REALM project, a multi-hospital voluntary surveillance network for monitoring multidrug-resistant organisms among Chicago hospital intensive care units and long-term acute care hospitals.
OPGN: 1.67 (unch)
OpGen to Present Data Showing Acuitas(R) Tests are Effective Tools for Investigating Transmission of "Super Bugs"
GlobeNewswire - Tue Sep 22, 7:15AM CDT
OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas Resistome Test and Acuitas Whole Genome Sequence (WGS) Analysis for multidrug-resistant organisms (MDROs) will be presented at the American Society for Microbiology's First Conference on Rapid Next-Generation Sequencing and Bioinformatic Pipelines for Enhanced Molecular Epidemiologic Investigation of Pathogens, to be held from September 24 to 27 in Washington, D.C.
OPGN: 1.67 (unch)
(0)
(0)Scroll down for more posts ▼